Drug Trial Radar · NCT06657144
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- Coherus Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Conditions
- Metastatic Solid Tumor
- Advanced Solid Tumor
Interventions
CHS-114Drug
Solution for infusion
ToripalimabDrug
Solution for infusion
5 FluorouracilDrug
Solution for infusion
CisplatinDrug
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until 90 days after the last dose of study drug (up to approximately 2.25 years)
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona · Withdrawn
City of Hope
Duarte, California · Recruiting
University of Colorado - Aurora Cancer Center
Aurora, Colorado · Recruiting
Winship Cancer Center - Emory University
Atlanta, Georgia · Recruiting
Ochsner Health
New Orleans, Louisiana · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
Comprehensive Cancer Center of Nevada
Las Vegas, Nevada · Recruiting
Christus St Vincent Regional Medical Center
Santa Fe, New Mexico · Recruiting
START New York
Lake Success, New York · Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
University of Pittsburg Medical Center _UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Prisma Health Cancer Institute
Greenville, South Carolina · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology - Central South
Austin, Texas · Recruiting
START San Antonio, LLC.
San Antonio, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
START Mountain Region, LLC.
West Valley City, Utah · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Withdrawn
Changhua Christian Hospital
Chang-hua, Taiwan · Recruiting
E-Da Cancer Hospital
Kaohsiung City, Taiwan · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
China Medical University Hospital
Taichung, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
Chi Mei Hospital
Tainan, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Mackay Memorial Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.